In-house roundup: US TERM Act is "blunt instrument"; SPC waiver prep begins; China patent amendment not enough; Insurtech filing surge to continue
Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX
Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

In-house roundup: US TERM Act is "blunt instrument"; SPC waiver prep begins; China patent amendment not enough; Insurtech filing surge to continue


Managing IP rounds up the latest news and analysis from in-house counsel in patent-focused businesses


US TERM bill is “blunt instrument” that would be disastrous say drug innovators

Proposed legislation in the US House of Representatives seeks to limit patent term extension for pharmaceutical products in a way that pharma innovators say would stifle innovation and not solve potential drug pricing problems. Read More...

SPC waiver: drug companies and patent offices start preparations

With the EU SPC Manufacturing Waiver due to come into force next week, innovators, generics and patent offices say that they are looking at which products might be affected and whether to charge notification fees. Read more...

Foreign businesses worried China’s Patent Law changes are too modest

In-house counsel say they would have preferred to have seen more robust changes in the fourth amendment to China’s Patent Law as well as better predictability of rulings. Read more...

Insurtech patent filings will grow as innovation becomes more important say insurance companies

With insurtech patents increasing by 40% in 2017, in-house counsel at Allstate, The Hartford and elsewhere say filings will continue to go up as they seek to become more customer-centric organisations. Read more...

more from across site and ros bottom lb

More from across our site

Michelle Lue-Reid has joined the IP business as its chief transformation officer and will look to implement major change initiatives across member firms
Chad Landmon, who joins in Washington DC, hopes to expand the firm’s Hatch-Waxman practice
The FRAND rate is only 5 cents higher than the per-device rate determined at first instance in 2023
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Nearly four months after joining Crowell & Moring, Edward Taelman reflects on starting afresh, new clients, and firm culture
Firms discuss the ebb and flow of life sciences IP work and explain how they help professionals pivot between specialities
Mercedes-Benz, Dolby Laboratories, and Panasonic discuss the merits and drawbacks of the USPTO's terminal disclaimer proposal
In-house counsel believe Chinese domestic firms are becoming as sophisticated as international firms, but they may not shift their portfolios just yet
The Court of Appeals for the Federal Circuit is looking to renew a ban that has prevented Judge Pauline Newman from hearing cases
The list of the top representative firms at the UPC may yield few surprises but their success did not come free
Gift this article